Blog

Primary market research (PMR) has long been a trusted advisor to brand teams, helping organizations understand customers, test assumptions, and reduce uncertainty in critical business decisions. Over the past decade, however, many PMR organizations have been asked to do more with...

Oncology markets are no longer defined only by tumor type or line of therapy. AI, patient-level data, and primary research now help teams define markets by biology, care pathways, and access barriers. That shift can shape development strategy, trial design, and...

Direct-to-patient (DTP) channels have quietly moved from the margins of pharma to a central lever in high-demand categories. One-third of new Zepbound prescriptions in the U.S. are now being filled through LillyDirect, bypassing insurers, PBMs, and traditional pharmacy channels entirely. A...

Scott Evangelista Chief Executive Officer When I sat down with Jane King on New to the Street, I had one message I wanted every viewer to walk away with. Trinity is the leader integrating human and artificial intelligence in commercialization. Life...

Pharmaceutical competitive intelligence (CI) has quietly become one of pharma’s most strained functions. The TGaS Competitive Intelligence Landscape Survey (October 2025) shows competitive complexity accelerating at a pace that traditional CI models cannot absorb.

You have used tools like ChatGPT. They are fast, helpful, almost fun. Then your company deploys its own AI platform and something feels off. It hedges. It refuses. It does not understand your business, markets, or data. You are not imagining...